Vitrolife Stock Price, News & Analysis

Vitrolife Group has acknowledged a PGT-A class action lawsuit filed against Vitrolife AB, Vitrolife Inc, and Igenomix USA in the Southern District of Florida court. The company has not yet been formally served with the complaint. The announcement notes that similar class actions were initiated against other industry peers providing PGT-A testing services during Q4 2024.

The company states it will evaluate the class action and its potential scope with US legal counsel and will provide market updates when additional information becomes available.

Vitrolife Group (VTRLY) has appointed Ermanno Sironi as Chief Operating Officer (COO), effective immediately. In this newly created role, Sironi will oversee three business areas: Consumables, Technologies, and Genetics, along with the IT organization. The appointment aligns with the company's strategy to enhance operational excellence, implement a scalable operating model, and optimize processes for synergies and digital productivity.

Sironi brings over 30 years of MedTech executive experience in Operations, Finance, and Business Development from global companies. He has been serving as a strategic advisor on operational excellence and business transformation to Vitrolife's executive management team over the past year.

Vitrolife AB reported strong Q4 2024 results with sales reaching SEK 959 million, up 6% in local currencies. Regional performance showed growth of 10% in EMEA and 9% in Americas, while APAC declined 2%. By business area, Consumables grew 12%, Technologies 9%, while Genetics remained flat.

The company's gross margin improved to 61.1% from 56.9%, while EBITDA increased to SEK 337 million with a margin of 35.1%. Net income recovered significantly to SEK 139 million from a loss of SEK 4,179 million, resulting in earnings per share of SEK 1.03.

For full-year 2024, sales reached SEK 3,609 million, showing 4% growth in local currencies. The Board proposed a dividend of SEK 1.10 per share, up from SEK 1.00 in the previous year. Operating cash flow for the year improved to SEK 907 million from SEK 757 million.

Vitrolife AB has announced a conference call to present its fourth quarter and full year report 2024. The presentation will be held in English on Thursday, January 30, 2025, at 10:00 AM CET. Participants must register online to receive telephone numbers and access PINs for the conference.

Key participants from Vitrolife include Bronwyn Brophy O'Connor (CEO) and Helena Wennerström (acting CFO). The full year report press release will be published at 8:00 AM CET on the same day, with presentation materials available on the company website before the call.

A recorded version of the conference call will be accessible for seven days via international phone number +44 (0) 20 3451 9993, using access code 2171635#. For investor relations inquiries, contact Amelie Wilson at awilson@vitrolife.com.

Vitrolife AB announces the departure of CFO Patrik Tolf due to personal reasons. Helena Wennerström has been appointed as acting CFO, bringing extensive experience from previous roles as CFO at ViaCon Group AB and EVP & CFO at Bulten AB. Wennerström will assume the position immediately, with Tolf supporting during a transition period. The company has initiated the recruitment process for a permanent CFO.

Vitrolife reported strong Q3 2024 performance with sales reaching SEK 867 million, showing a 7% increase in local currencies. The company saw regional growth of 9% in EMEA, 2% in Americas, and 9% in APAC. Business areas showed varied performance with Consumables up 13%, Technologies up 11%, while Genetics remained flat. The gross margin improved to 58.6% from 55.7%. EBITDA reached SEK 289 million with a 33.4% margin. For the first nine months, total sales were SEK 2,650 million, with a 4% increase in local currencies and improved EBITDA of SEK 888 million.

Vitrolife AB (publ) has announced a conference call to present its Q3 2024 interim report. The call is scheduled for Thursday, October 24, 2024, at 10:00 AM CET. Participants must register in advance to receive access details. The presentation will be conducted in English.

Key participants from Vitrolife include CEO Bronwyn Brophy O'Connor and CFO Patrik Tolf. The interim report press release will be issued at 8:00 AM CET on the same day, with presentation materials available on the company's website prior to the call.

A recorded version of the conference call will be accessible for seven days following the event. The company emphasizes that personal data will be processed in accordance with their privacy policy.

Vitrolife AB (publ) has announced the appointment of its election committee for the Annual General Meeting in 2025. The committee members are:

• Niels Jacobsen, appointed by William Demant Invest A/S
• Patrik Tigerschiöld, appointed by Bure Equity AB
• Patricia Hedelius, appointed by AMF Fonder & Pension
• Jón Sigurdsson, Chairman of the Board

The appointments follow the principles determined at the Annual General Meeting on April 25, 2024. The upcoming Annual General Meeting will be held on April 29, 2025 in Gothenburg. Shareholders wishing to propose items for consideration must submit their requests to the Board at least seven weeks before the meeting.

Vitrolife AB (publ) reported strong Q2 2024 results, with sales reaching SEK 941 million, a 4% increase in both local currencies and SEK. The company saw significant growth in its Technologies business area, up 40% in local currencies. Gross margin improved to 59.9%, while EBITDA increased to SEK 327 million with a margin of 34.7%. Net income rose to SEK 143 million, resulting in earnings per share of SEK 1.06.

Regionally, EMEA led growth at 11%, followed by Americas at 5%, while APAC declined by 5%. Vitrolife also made strategic acquisitions, including EMB's distribution activities and eFertility. The first half of 2024 showed overall positive trends, with improved financial metrics across the board.